Published in Invest Ophthalmol Vis Sci on May 14, 2012
Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog Retin Eye Res (2013) 1.06
Progress in corneal wound healing. Prog Retin Eye Res (2015) 1.02
Nanotechnology approaches for ocular drug delivery. Middle East Afr J Ophthalmol (2013) 1.00
Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration. ACS Nano (2013) 0.91
Polymer nanoparticles for drug and small silencing RNA delivery to treat cancers of different phenotypes. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2013) 0.90
Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy. Br J Pharmacol (2013) 0.83
Topical Use of Angiopoietin-like Protein 2 RNAi-loaded Lipid Nanoparticles Suppresses Corneal Neovascularization. Mol Ther Nucleic Acids (2016) 0.82
Nanotechnology in corneal neovascularization therapy--a review. J Ocul Pharmacol Ther (2013) 0.79
Targeting herpetic keratitis by gene therapy. J Ophthalmol (2012) 0.76
Nanomedicine approaches for corneal diseases. J Funct Biomater (2015) 0.75
Gene therapy in corneal transplantation. Semin Ophthalmol (2013) 0.75
Nanoengineering of therapeutics for retinal vascular disease. Eur J Pharm Biopharm (2015) 0.75
Preparation of arginine-glycine-aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization. Int J Nanomedicine (2016) 0.75
Subconjunctival injection of antagomir-21 alleviates corneal neovascularization in a mouse model of alkali-burned cornea. Oncotarget (2016) 0.75
Angiogenesis as a therapeutic target. Nature (2005) 11.89
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res (1997) 7.95
Biodegradable long-circulating polymeric nanospheres. Science (1994) 7.46
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature (2008) 7.10
VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer (2002) 5.96
Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol (2004) 5.40
Corneal avascularity is due to soluble VEGF receptor-1. Nature (2006) 4.77
A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells. Nat Biotechnol (2006) 3.46
Corneal neovascularization. Curr Opin Ophthalmol (2001) 3.22
Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med (2009) 2.39
Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc (2006) 2.12
PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst (2004) 2.01
siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev (2009) 1.91
Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1. Gene Ther (2006) 1.86
Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci (1998) 1.77
Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis. Am J Pathol (2004) 1.70
Nonviral methods for siRNA delivery. Mol Pharm (2009) 1.50
Rapid ocular angiogenic control via naked DNA delivery to cornea. Invest Ophthalmol Vis Sci (2001) 1.36
Immune privilege and angiogenic privilege of the cornea. Chem Immunol Allergy (2007) 1.29
Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J Pharm Pharmacol (2005) 1.28
Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol (2007) 1.28
Nanoparticles sustain expression of Flt intraceptors in the cornea and inhibit injury-induced corneal angiogenesis. Invest Ophthalmol Vis Sci (2007) 1.25
Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Am J Ophthalmol (2009) 1.23
Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol Vis (2008) 1.15
Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol (2009) 1.12
Lipid-mediated delivery of brain-specific angiogenesis inhibitor 1 gene reduces corneal neovascularization in an in vivo rabbit model. Gene Ther (2005) 1.07
Inhibition of corneal neovascularization with endostatin delivered by adeno-associated viral (AAV) vector in a mouse corneal injury model. J Biomed Sci (2007) 1.03
Biodegradable PLGA based nanoparticles for sustained regional lymphatic drug delivery. J Pharm Sci (2010) 1.01
Topical application of methotrexate for inhibition of corneal angiogenesis. Graefes Arch Clin Exp Ophthalmol (1999) 1.00
Sustained VEGF delivery via PLGA nanoparticles promotes vascular growth. Am J Physiol Heart Circ Physiol (2010) 0.95
Bevacizumab (avastin) and argon laser to treat neovascularization in corneal transplant surgery. Cornea (2008) 0.94
High loading efficiency and sustained release of siRNA encapsulated in PLGA nanoparticles: quality by design optimization and characterization. Eur J Pharm Biopharm (2010) 0.94
Unique homologous siRNA blocks hypoxia-induced VEGF upregulation in human corneal cells and inhibits and regresses murine corneal neovascularization. Cornea (2007) 0.93
Inhibition of retinal neovascularization by siRNA targeting VEGF(165). Mol Vis (2008) 0.93
Targeted drug and gene delivery systems for lung cancer therapy. Clin Cancer Res (2009) 0.92
Surface-functionalized nanoparticles for targeted gene delivery across nasal respiratory epithelium. FASEB J (2009) 0.88
Functionalized STAT1 siRNA nanoparticles regress rheumatoid arthritis in a mouse model. Nanomedicine (Lond) (2011) 0.87
Inhibition of vascular endothelial growth factor receptor signaling in angiogenic tumor vasculature. Adv Genet (2009) 0.86
Progress in siRNA delivery using multifunctional nanoparticles. Methods Mol Biol (2010) 0.84
The mechanisms on apoptosis by inhibiting VEGF expression in human breast cancer cells. Int Immunopharmacol (2009) 0.84
Effect of low molecular weight heparan sulphate on angiogenesis in the rat cornea after chemical cauterization. J Ocul Pharmacol (1994) 0.84
Efficient nanoparticle mediated sustained RNA interference in human primary endothelial cells. Nanotechnology (2011) 0.81
[Neovascularisation of the cornea]. Klin Monbl Augenheilkd (2005) 0.79
A siRNA targeting vascular endothelial growth factor-A inhibiting experimental corneal neovascularization. Curr Eye Res (2010) 0.79
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature (2008) 7.10
An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice. Nat Med (2003) 6.61
Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol (2003) 5.22
Corneal avascularity is due to soluble VEGF receptor-1. Nature (2006) 4.77
Toll-like receptor 3 and geographic atrophy in age-related macular degeneration. N Engl J Med (2008) 4.46
DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature (2011) 3.90
Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A (2006) 3.25
Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci (2003) 3.17
Wnt5a functions in planar cell polarity regulation in mice. Dev Biol (2007) 2.85
DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. Cell (2012) 2.81
Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med (2009) 2.39
CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature (2009) 2.39
MicroRNAs as modulators of smoking-induced gene expression changes in human airway epithelium. Proc Natl Acad Sci U S A (2009) 2.37
Regulation of polarized extension and planar cell polarity in the cochlea by the vertebrate PCP pathway. Nat Genet (2005) 2.36
Smoking-induced gene expression changes in the bronchial airway are reflected in nasal and buccal epithelium. BMC Genomics (2008) 2.11
Recent duplications dominate NBS-encoding gene expansion in two woody species. Mol Genet Genomics (2008) 2.04
Structural specializations of A2, a force-sensing domain in the ultralarge vascular protein von Willebrand factor. Proc Natl Acad Sci U S A (2009) 1.91
A mechanically stabilized receptor-ligand flex-bond important in the vasculature. Nature (2010) 1.90
Engineering hydrogels as extracellular matrix mimics. Nanomedicine (Lond) (2010) 1.86
Airway PI3K pathway activation is an early and reversible event in lung cancer development. Sci Transl Med (2010) 1.84
A dynamic bronchial airway gene expression signature of chronic obstructive pulmonary disease and lung function impairment. Am J Respir Crit Care Med (2013) 1.73
Growth factor gradients via microsphere delivery in biopolymer scaffolds for osteochondral tissue engineering. J Control Release (2008) 1.72
Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci U S A (2008) 1.70
Concern Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts. Arch Ophthalmol (2011) 1.69
Intravitreal Poly(L-lactide) Microparticles Sustain Retinal and Choroidal Delivery of TG-0054, a Hydrophilic Drug Intended for Neovascular Diseases. Drug Deliv Transl Res (2011) 1.58
Cyclic AMP-induced forkhead transcription factor, FKHR, cooperates with CCAAT/enhancer-binding protein beta in differentiating human endometrial stromal cells. J Biol Chem (2002) 1.58
Soluble vascular endothelial growth factor receptor 3 is essential for corneal alymphaticity. Blood (2013) 1.56
Hybrid dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration. ACS Nano (2012) 1.56
Silk-based electrospun tubular scaffolds for tissue-engineered vascular grafts. J Biomater Sci Polym Ed (2008) 1.55
HTRA1 variant confers similar risks to geographic atrophy and neovascular age-related macular degeneration. Cell Cycle (2007) 1.53
Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Invest Ophthalmol Vis Sci (2006) 1.52
Cesarean section reduces perinatal transmission of hepatitis B virus infection from hepatitis B surface antigen-positive women to their infants. Clin Gastroenterol Hepatol (2013) 1.51
Influence of drug solubility and lipophilicity on transscleral retinal delivery of six corticosteroids. Drug Metab Dispos (2011) 1.48
Increased expression of multifunctional serine protease, HTRA1, in retinal pigment epithelium induces polypoidal choroidal vasculopathy in mice. Proc Natl Acad Sci U S A (2011) 1.45
Genetic association of LOXL1 gene variants and exfoliation glaucoma in a Utah cohort. Cell Cycle (2008) 1.43
Transcriptional profiles of drought-responsive genes in modulating transcription signal transduction, and biochemical pathways in tomato. J Exp Bot (2010) 1.42
Similarities and differences between smoking-related gene expression in nasal and bronchial epithelium. Physiol Genomics (2009) 1.42
Essential role of Elovl4 in very long chain fatty acid synthesis, skin permeability barrier function, and neonatal survival. Int J Biol Sci (2007) 1.40
Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia. J Lipid Res (2008) 1.36
Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A. J Clin Invest (2006) 1.36
Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth. Proc Natl Acad Sci U S A (2009) 1.36
Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci (2003) 1.34
The tight junction protein, occludin, regulates the directional migration of epithelial cells. Dev Cell (2010) 1.32
Periocular routes for retinal drug delivery. Expert Opin Drug Deliv (2004) 1.31
Contributions of molecular binding events and cellular compliance to the modulation of leukocyte adhesion. J Cell Sci (2003) 1.31
Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur J Pharmacol (2005) 1.30
Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J Pharm Pharmacol (2005) 1.28
Effect of eye pigmentation on transscleral drug delivery. Invest Ophthalmol Vis Sci (2008) 1.25
Nanoparticles sustain expression of Flt intraceptors in the cornea and inhibit injury-induced corneal angiogenesis. Invest Ophthalmol Vis Sci (2007) 1.25
Soluble vascular endothelial growth factor receptor-1 contributes to the corneal antiangiogenic barrier. Br J Ophthalmol (2006) 1.22
Pro-proliferative factor KLF5 becomes anti-proliferative in epithelial homeostasis upon signaling-mediated modification. J Biol Chem (2008) 1.21
Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur J Pharmacol (2003) 1.19
Bovine and porcine transscleral solute transport: influence of lipophilicity and the Choroid-Bruch's layer. Invest Ophthalmol Vis Sci (2006) 1.18
Force and Compliance Measurements on Living Cells Using Atomic Force Microscopy (AFM). Biol Proced Online (2004) 1.18
Force spectroscopy of LFA-1 and its ligands, ICAM-1 and ICAM-2. Biomacromolecules (2006) 1.18
Insoluble and flexible silk films containing glycerol. Biomacromolecules (2010) 1.18
Corneal transparency: genesis, maintenance and dysfunction. Brain Res Bull (2009) 1.18
Mediators of ocular angiogenesis. J Genet (2009) 1.17
Tissue-type plasminogen activator and the low-density lipoprotein receptor-related protein induce Akt phosphorylation in the ischemic brain. Blood (2008) 1.17
Development and in-vitro evaluation of sustained release poloxamer 407 (P407) gel formulations of ceftiofur. J Control Release (2002) 1.17
Controlled release from multilayer silk biomaterial coatings to modulate vascular cell responses. Biomaterials (2007) 1.17
Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest Ophthalmol Vis Sci (2010) 1.17
UNC-108/RAB-2 and its effector RIC-19 are involved in dense core vesicle maturation in Caenorhabditis elegans. J Cell Biol (2009) 1.16
Development of an in vitro multicellular tumor spheroid model using microencapsulation and its application in anticancer drug screening and testing. Biotechnol Prog (2005) 1.16
Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm Res (2004) 1.15
Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR). Invest Ophthalmol Vis Sci (2010) 1.15
Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. Mol Vis (2008) 1.15
Biomaterials from ultrasonication-induced silk fibroin-hyaluronic acid hydrogels. Biomacromolecules (2010) 1.14
Retracted Influence of lipophilicity on drug partitioning into sclera, choroid-retinal pigment epithelium, retina, trabecular meshwork, and optic nerve. J Pharmacol Exp Ther (2009) 1.14
CD44+/CD24- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma. J Exp Clin Cancer Res (2012) 1.14
Flt-1 intraceptors inhibit hypoxia-induced VEGF expression in vitro and corneal neovascularization in vivo. Invest Ophthalmol Vis Sci (2005) 1.13
Rapidly evolving R genes in diverse grass species confer resistance to rice blast disease. Proc Natl Acad Sci U S A (2013) 1.10
A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications. Pharm Res (2002) 1.10
Short-interfering RNAs induce retinal degeneration via TLR3 and IRF3. Mol Ther (2011) 1.09
Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage. Diabetes (2009) 1.08
Induction of fibroblasts to neurons through adenoviral gene delivery. Cell Res (2011) 1.08
Corneal stroma PDGF blockade and myofibroblast development. Exp Eye Res (2008) 1.08
Electrospun silk material systems for wound healing. Macromol Biosci (2010) 1.08
Anterior chamber intraocular lens, sutured posterior chamber intraocular lens, or glued intraocular lens: where do we stand? Curr Opin Ophthalmol (2012) 1.07
Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1. Elife (2013) 1.06
Pluronic F127 gel formulations of deslorelin and GnRH reduce drug degradation and sustain drug release and effect in cattle. J Control Release (2002) 1.06
The concentration of CYFRA 21-1, NSE and CEA in cerebro-spinal fluid can be useful indicators for diagnosis of meningeal carcinomatosis of lung cancer. Cancer Biomark (2013) 1.05
Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR). Pharm Res (2008) 1.05
Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma. Arch Ophthalmol (2009) 1.05
Acidic nanoparticles are trafficked to lysosomes and restore an acidic lysosomal pH and degradative function to compromised ARPE-19 cells. PLoS One (2012) 1.05
Nanomicellar formulations for sustained drug delivery: strategies and underlying principles. Nanomedicine (Lond) (2010) 1.04
Green process to prepare silk fibroin/gelatin biomaterial scaffolds. Macromol Biosci (2010) 1.04
Rescue of photoreceptor degeneration by curcumin in transgenic rats with P23H rhodopsin mutation. PLoS One (2011) 1.01
Preparation of budesonide and budesonide-PLA microparticles using supercritical fluid precipitation technology. AAPS PharmSciTech (2002) 1.01
Myeloma cells inhibit osteogenic differentiation of mesenchymal stem cells and kill osteoblasts via TRAIL-induced apoptosis. Arch Med Sci (2010) 1.00
Influence of dosage form on the intravitreal pharmacokinetics of diclofenac. Invest Ophthalmol Vis Sci (2009) 1.00
Morpholino-mediated increase in soluble Flt-1 expression results in decreased ocular and tumor neovascularization. PLoS One (2012) 1.00